Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL305249 | 0.71 | CYP3A4 (0.35) | CYP3A4KDM4EALDH1A1MAPTLMNA | |
| SCHEMBL28999586 | 0.68 | — | — | |
| SCHEMBL596262 | 0.67 | — | — | |
| SCHEMBL2819250 | 0.67 | — | — | |
| SCHEMBL5072 | 0.66 | — | — | |
| SCHEMBL4337709 | 0.65 | KMT2A (0.41) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL749892 | 0.65 | PIK3CD (0.58) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL5418820 | 0.64 | KMT2A (0.48) | KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL3042153 | 0.64 | KDM4E (0.45) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL424589 | 0.64 | KMT2A (0.39) | KMT2AMEN1CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070161677-A1 | Bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191444-A1 | Benzimidazolyl derivatives | JAK1, MARK1, RAF1 | KMT2A 2009/4885MEN1 1171/4885CYP3A4 1881/4885 |
| US-20070161677-A1 | Bisarylurea derivatives | BRAF, RAF1, NRAS | KMT2A 1891/4885MEN1 1579/4885CYP3A4 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.